Held in Rio de Janeiro, the 21st International Myeloma Society (IMS) Meeting and Exposition, in combination with the 8th Nursing and Allied Health Symposium brought together myeloma specialists from around the globe. The events spanned 25–28th September 2024 and Myeloma UK’s attendance ensured our contributions to myeloma patient care were shared on the international stage.
At the Nursing and Allied Health Symposium, Myeloma UK once again had a key role in planning and delivering the multidisciplinary programme, whilst at IMS we showcased our educational initiatives for primary care and laboratory staff; resources produced in collaboration with a panel of multidisciplinary experts.
Myeloma UK champions multidisciplinary excellence at Nursing and Allied Health Symposium
Myeloma UK’s Clinical Practice Manager, Monica Morris, co-chaired multidisciplinary panel discussion of real-world solutions to current issues in treatment delivery.
This year there was a strong UK multidisciplinary involvement in planning and delivering the meeting, with Monica Morris, Clinical Practice Programme Manager on the Nurse Standing Committee.
Bringing expert nurses, allied health professionals and clinicians together, the meeting encompassed the holistic management of precursor disease, strategies to improve bone health, and management of new treatments. There was also a slot devoted to discussing practical solutions to the challenges healthcare systems face in delivering more treatments to more myeloma patients year on year, with Dr Vincent Rajkumar sharing insights on treatment dosing and scheduling in the real-world setting.
Expert speakers included Professor Kwee Yong talking about the biological and psychological uncertainties in precursor disease, Dr Orla McCourt discussing the role of targeted exercise programmes and Andrea Preston contributing the pharmacist perspective within the panel discussion on managing capacity in clinic. Poster presentations featured excellent representation from UK nurses and allied healthcare professionals.
Oral abstracts topics included: bispecific antibody side-effect management; step-up dosing of bispecific antibodies; models of MGUS monitoring and new approaches in steroid symptom monitoring.
Explore more of the topics discussed at this annual meeting, view the full programme here >
Myeloma UK demonstrates the power of multidisciplinary collaboration for myeloma diagnosis
Myeloma UK’s Head of Clinical Practice, Suzanne Renwick, presented an informative poster at IMS, summarising the work of the Myeloma UK Early Diagnosis Steering Committee.
Myeloma UK’s Head of Clinical Practice, Suzanne Renwick, presented an informative poster at IMS, summarising the work of the Myeloma UK Early Diagnosis Steering Committee.
Entitled ‘Improving diagnosis of myeloma in the UK: the power of multidisciplinary collaboration’, the poster described the work of the steering committee in developing a wide array of respected myeloma educational resources and practical tools for GPs and laboratory staff. This multidisciplinary approach is invaluable in addressing complex issues that can lead to a delayed diagnosis.
Poster presented by Suzanne Renwick, Head of Clinical Practice. Click for larger image.
Showcase your work at IMS
As a dedicated meeting for myeloma, IMS is an incredible opportunity for education and networking, as well as hearing the latest research and trial developments.
Get involved at IMS 2025 (Toronto) and IMS 2026 (Glasgow) – start planning your abstract to showcase your work! Keep an eye out on the Myeloma UK HCP Hub for more about these meetings next year. To make sure you are among the first to discover all that the HCP Hub has to offer join our waitlist here >